Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment

Autores

  • Ana Paula do Nascimento Antonio National Cancer Institute José Alencar Gomes da Silva (INCA). Cancer Hospital II (HCII). Rio de Janeiro (RJ), Brazil.
  • Thiago Ribeiro Nery Fundação Getúlio Vargas (FGV). Rio de Janeiro (RJ), Brazil.
  • Liliana Rosa Alves Manaças National Cancer Institute José Alencar Gomes da Silva (INCA). Cancer Hospital II (HCII). Rio de Janeiro (RJ), Brazil.
  • Priscila Helena Marietto Figueira National Cancer Institute José Alencar Gomes da Silva (INCA). Cancer Hospital II (HCII). Rio de Janeiro (RJ), Brazil.

DOI:

https://doi.org/10.32635/2176-9745.RBC.2022v68n1.1879

Palavras-chave:

genital neoplasms, female, drug-related side effects and adverse reactions, antineoplastic agents, withholding treatment

Resumo

Introduction: The evaluation of the causes of interruption of the antineoplastic therapeutic plan allows the development of strategies that increase adherence and positive treatment outcomes. Objective: Outline the clinical profile of the patients with gynecological tumors under intravenous antineoplastic treatment, identifying the risk of interrupting the therapeutic plan. Method: Retrospective and quantitative study (2011-2018), including patients older than 18 years old, with gynecological tumors undergoing antineoplastic treatment. The database was built from the spreadsheets of antineoplastic drug handling at the Chemotherapy Center. The variables collected were: year of treatment, age, type of tumor, purpose of treatment, protocol, medication, dose, start and end of treatment, and treatment interruption. Results: 6,496 patients over 8 years were evaluated. Fifty two percent of the patients presented cervical cancer. Almost forty eight percent (47.6%) showed a palliative treatment purpose for their tumors. Approximately, twenty three percent (22.6%) interrupted the antineoplastic treatment. For adjuvant, curative, and palliative purposes the age range 18-30 presented the highest interruption, respectively 33%, 36% and 41%. The paclitaxel/carboplatin protocol was the most prescribed with a significant percentage of interruption. Conclusion: The findings suggest that there is an association between treatment discontinuation and patients’ age and therapeutic purpose.

Downloads

Não há dados estatísticos.

Downloads

Publicado

2021-12-23

Como Citar

1.
Antonio AP do N, Nery TR, Manaças LRA, Figueira PHM. Evaluation of the Clinical Profile of Patients with Gynecological Tumors undergoing Antineoplastic Treatment. Rev. Bras. Cancerol. [Internet]. 23º de dezembro de 2021 [citado 22º de janeiro de 2022];68(1):e-011879. Disponível em: https://rbc.inca.gov.br/revista/index.php/revista/article/view/1879

Edição

Seção

ARTIGO ORIGINAL